- 期刊
Cytokines as Biomarkers of Treatment Response to IFNβ in Relapsing-Remitting Multiple Sclerosis
延伸閱讀
- Lee, H. T., Chen, W. S., Chen, M. H., Tsai, C. Y., & Chou, C. T. (2009). The Expression of Proinflammatory Cytokines and Intracellular Minerals in Patients with Ankylosing Spondylitis. Formosan Journal of Rheumatology, 23(1), 40-46. https://doi.org/10.6313/FJR.2009.23(01).07
- Williams, A. E., Vietri, J. T., Isherwood, G., & Flor, A. (2014). Symptoms and Association with Health Outcomes in Relapsing-Remitting Multiple Sclerosis: Results of a US Patient Survey. Multiple Sclerosis International, (2014), 35-42. https://doi.org/10.1155/2014/203183
- Sena, V. F., Silva, A. M. E., Sena, A., Cavaleiro, I., Vale, J., Derudas, B., Gbaguidi, G. C., & Staels, B. (2016). Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Research, 2016(), 176-180. https://doi.org/10.1155/2016/5716415
- Anagnostouli, S. K. A. M. (2013). Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Multiple Sclerosis International, 2013(), 95-114. https://doi.org/10.1155/2013/340508
- Lavery, A. M., Verhey, L. H., & Waldman, A. T. (2014). Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials. Multiple Sclerosis International, (2014), 43-55. https://doi.org/10.1155/2014/262350